

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
25 July 2024 (25.07.2024)



(10) International Publication Number
WO 2024/153794 A1

(51) International Patent Classification:

C12N 15/62 (2006.01) C07K 14/005 (2006.01)
A61K 39/12 (2006.01) C07K 16/10 (2006.01)
A61K 39/215 (2006.01)

(21) International Application Number:

PCT/EP2024/051253

(22) International Filing Date:

19 January 2024 (19.01.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/480,754 20 January 2023 (20.01.2023) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151 85
Södertälje (SE).

(72) Inventors: **LOO, Yueh-Ming**; MEDIMMUNE, LLC,
One MedImmune Way, Gaithersburg, Maryland 20878
(US). **FRANCICA, Joseph Richard**; ASTRAZENECA
PHARMACEUTICALS LP, 1800 Concord Pike, P.O. Box
15437, Wilmington, Delaware 19850-5437 (US). **BLAIR,
Wade Stanton**; ASTRAZENECA PHARMACEUTICALS
LP, 1800 Concord Pike, P.O. Box 15437, Wilming-
ton, Delaware 19850-5437 (US). **LALIBERTE, Jason
Paul**; ASTRAZENECA PHARMACEUTICALS LP, 1800
Concord Pike, P.O. Box 15437, Wilmington, Delaware
19850-5437 (US).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPER-
TY**; Eastbrook House, Shaftesbury Road, CAMBRIDGE,
Cambridgeshire CB2 8BF (GB).


(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

(54) Title: VACCINE



(57) Abstract: The present disclosure relates to methods of inducing a pan-sarbecoronavirus variant immune response for the treatment and prevention of coronavirus infections.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*